Mindstrong's patented science and technology was developed by Dr. Dagum, and is based on four years of extensive clinical studies applying machine intelligence to human-computer interactions patterns. Mindstrong products are in clinical trials in numerous partnership projects with payers, providers, academics and the pharmaceutical industry to bring these new tools to bear on answering the most fundamental questions in behavioral health.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
06/15/17	$14,000,000	Series A	ARCH Venture Partners Berggruen Holdings Foresite Capital One Mind Brain Health Impact Fund Optum Ventures	undisclosed
06/14/18	$15,000,000	Series B	ARCH Venture Partners Decheng Capital Foresite Capital Optum Ventures	undisclosed
05/21/20	$100,000,000	Series C	ARCH Venture Partners Foresite Capital Optum Ventures What If Ventures	undisclosed